Study Design

A FOAM TO ADDRESS
THE DIVERSE NEEDS OF
SEBORRHEIC DERMATITIS
PATIENTS

Not a steroid. No boxed warning
ZORYVE (roflumilast) topical foam 0.3%ZORYVE (roflumilast) topical foam 0.3%
Simple once-daily treatmentSimple once-daily treatment

For age 9+

FIRST-IN-CLASS FOR SEBORRHEIC DERMATITIS2

STRATUM and Trial 203 pivotal study designs1,2:

  • Two multicenter, randomized, double-blind,
    vehicle-controlled studies
  • 683 participants with moderate to severe
    seborrheic dermatitis
    • STRATUM: ZORYVE foam = 304, vehicle = 153
    • Trial 203: ZORYVE foam = 154, vehicle = 72
  • Once daily for 8 weeks
See eligibility criteria

No concomitant therapies or other moisturizers/emollients were allowed on treated areas2

Primary Endpoint

Key Secondary Endpoints In STRATUM

IGA Success at Week 8

Achievement of an IGA score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline

IGA = Investigator Global Assessment.

IGA 0 at Week 8

Achievement of completely Clear skin (IGA = 0)3

WI-NRS Success at Weeks 2, 4, and 8

Achievement of a ≥4-point improvement for patients with a baseline score of ≥43

IGA = Investigator Global Assessment; WI-NRS = Worst-Itch Numeric Rating Scale.

73% of patients had involvement in multiple areas in STRATUM2

Image of scalp before using ZORYVE for 8 Weeks

SCALP

Image of face before using ZORYVE for 8 Weeks

FACIAL

Image of eyelid before using ZORYVE for 8 Weeks

EYELIDS

Image of ear before using ZORYVE for 8 Weeks

EARS

Image of trunk before using ZORYVE for 8 Weeks

TRUNK

Actual clinical trial patients

Simple application anywhere:

Shake
Dispense
Apply

Please see Instructions For Use for additional information.

See
Efficacy Data

View
Safety Profile

Request a
Representative